tbuckley/cabot-search huggingface dataset:
Can axillary dissection be avoided in patients with sentinel lymph node (SLN) metastases (mets)?
Authors: A. Katz, I. Gage, S. Evans, M. Shaffer, T. Fleury, P. Petrucci, F. Smith, M. Palmer, R. Flax, C. Drogula, C. Magnant
Journal: Journal of Clinical Oncology (2005)

573 Background: Which patients should undergo a completion axillary dissection following identification of a + SLN is controversial. Methods: 1135 patients underwent SLN mapping using blue dye and radiocolloid from 1998–2003. The results of hematoxylin and eosin (H&E) staining are included. Results: 1150 SLN procedures were performed on 1135 patients. Tumor size ranged from 0.1- 9.0 cm (median=1.5 cm). 297 procedures yielded + SLNs. Predictors of + SLNs included histology (4% for DCIS vs. 28% for invasive disease, p<0.001), and for those with invasive disease the size of the primary tumor (10%, 30%, 47% and 60% for patients with tumors ≤1 cm, 1.1–2.0 cm, 2.1–5.0 cm and >5 cm, respectively, p<0.001) and the presence of lymphvascular space invasion (LVSI) (62 vs.22%, p<0.001). For patients with a + SLN, the size of the largest SLN mets was predictive of additional + nonSLNs (20%, 23%, 55% and 63% for patients with SLN mets ≤2.0 mm, 2.0–4.0 mm, 4.0–10.0 mm and >10.0 mm, respectively, p<0.001) as was LVSI (55 vs. 36%, p=0.02). The size of the primary tumor, the number of +SLNs and extranodal extension (ENE) were not predictive of + nonSLNs. Predictors of ≥4 + nodes included the size of the largest SLN mets (2%, 5%, 25% and 36% for patients with SLN mets ≤2.0 mm, 2.0–4.0 mm, 4.0–10.0 mm and >10.0 mm, respectively, p<0.001), the size of the primary tumor (12%, 12%, 26% and 43% for patients with invasive tumors ≤1 cm, 1.1–2.0 cm, 2.1–5.0 cm and >5 cm, respectively, p<0.001), the number of + SLNs (12% for 1 + SLN, 31% for 2, and 64% for ≥3, p<0.001), and LVSI (27 vs. 14%, p=0.01). ENE was not predictive of ≥4 + nodes. While the patient numbers were small, for the select subgroup of patients with SLN mets ≤2.0 mm, primary tumor size ≤1 cm and no LVSI, 43% (3/7) had additional + nonSLNs. None had ≥4 + nodes. Conclusions: The size of the SLN mets and the presence of LVSI predicted for the positivity of nonSLNs; however, no subgroup was identified that did not have a significant rate of nonSLN involvement on completion axillary dissection. A definitive answer to this question awaits the results of ongoing randomized trials. In the interim, our data does not support eliminating a completion axillary dissection for any subgroup of patients with + SLNs. No significant financial relationships to disclose.
CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation.
Authors: Steffen Koschmieder, Francesco D′Alo′, Hanna Radomska, Susumu Kobayashi, Elena Levantini, Nanjoo Suh, Michael B. Sporn, Annalisa Di Ruscio, Maria Teresa Voso, Wolfgang E. Berdel, Carsten Müller-Tidow, Hubert Serve, Daniel G. Tenen
Journal: Blood (2005)
Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome.
Authors: Josephine Cunanan, Michelle Kujawski, He Zhu, Margaret Prechel, Jeanine Walenga, Debra Hoppensteadt, Jawed Fareed
Journal: Blood (2007)
Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.
Authors: Sean Whittaker, Ellen J Kim, Miles Prince, Marie France Demierre, Cynthia Giver, Sagar Lonial, Richard Piekarz, Youn H Kim, Jean Nichols, Darrell Nix, Susan Bates
Journal: Blood (2009)
Hypoalbuminemia (&amp;lt; 3.0 g/dl) and Poor Karnofsky Performance Score (&amp;lt;80) at Day 90 Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory and Pharmacologic Parameters
Authors: Mohamed A Kharfan-Dabaja, Julio C. Chavez, Eduardo Ivan Fernandez-Vertiz, Daohai Yu, Weiwei Zhu, Janelle Perkins, Teresa Field, Ernesto Ayala, Hugo F. Fernandez, Melissa Alsina, Lia Perez, Jyotishankar Raychaudhuri, J. Leonel Ochoa-Bayona, Linda Brand, Dan Sullivan, Claudio Anasetti
Journal: Blood (2008)
B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.
Authors: Sameer Tulpule, George Mikhaeel, Majid Kazmi, Tom Nunan, John Van Der Walt, David Goldsmith, Paul A. Fields
Journal: Blood (2005)
Case 1-2017
Authors: M.-Marsel Mesulam, Bradford C. Dickerson, Janet C. Sherman, Daisy Hochberg, R. Gilberto Gonzalez, Keith A. Johnson, Matthew P. Frosch
Journal: New England Journal of Medicine (2017)

A 70-year-old woman presented with gradually progressive aphasic impairment of word finding, object naming, and word comprehension; other areas of cognition were mostly intact. A clinical diagnosis was made, and additional tests were performed.
Single Cell Network Profiling (SCNP) of Early-Stage Chronic Lymphocytic Leukemia (CLL): Association with p53, IGHV Mutational Status and Time to First Treatment (TTFT)
Authors: Jason Ptacek, Erik Evensen, Rachael E. Hawtin, Greg Friedland, Jodi R. Ware, James Cordeiro, Nadia Peragine, Alessandra Cesano, Robin Foà, Anna Guarini
Journal: Blood (2012)
CKS1B Mediates SKP2/p27Kip1-Independent Myeloma Cell Survival and Disease Progression through Activation of MEK/ERK and JAK/STAT3 Signaling Pathways.
Authors: Fenghuang Zhan, Lei Shi, Siqing Wang, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Maurizio Zangari, Guiyuan Li, Guido J. Tricot
Journal: Blood (2009)
Correlation between FOXP3 Gene Polymorphisms in Donors, and the Severity of Acute Graft-Versus-Host Disease in Patients after Related Allogeneic Stem Cell Transplantation.
Authors: Yocanxochitl Perfecto-Avalos, Jose R. Borbolla Escoboza, Luis M. Villela-Martiez, Sean P. Scott, Jorge Vela-Ojeda, Oscar Gonzalez-Ramella, Severiano Baltazar-Arellano, Manuel A. Lopez-Hernandez
Journal: Blood (2007)
Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study
Authors: A. Gennari, P. Conte, O. Nanni, L. Manzione, E. Cortesi, C. Boni, L. Del Mastro, P. Bruzzi, V. Lo Russo, M. de Lena, D. Amadori
Journal: Journal of Clinical Oncology (2005)

522 Background: To evaluate the role of maintenance treatment with P after Ist line CT with an antracycline-paclitaxel containing regimen in MBC, in terms of Progression free Survival (PFS). Methods: MBC pts received induction CT with one of the following regimens (induction phase): A) Epirubicin (E) 90 mg/sqm + Paclitaxel (P) 200 mg/sqm (3 hrs), Q 3 weeks; B) Doxorubicin (D) 50 mg/sqm 16 hrs before P 200 mg/sqm (3 hrs) Q 3 weeks; C) D 50 mg/sqm day 1 + P 200 mg/sqm day 2 (3 hrs) Q 3 weeks for a maximum of 8 courses. Pts who achieved a response or SD were randomised to receive P 175 mg/m2 Q 3 weeks for 8 additional courses or control (no CT). The initial hypothesis was that maintenance CT could induce a 3 month absolute improvement of PFS in responding (or SD) patients. Planned sample size was 400 patients, to be enrolled in 2 yr period with an additional 2 yr period follow up. Results: from April 1998 to August 2003, 451 MBC pts have entered the induction phase, of these 253 have been randomised, by 22 italian centers. Due to the low accrual rate, in June 2003 an unplanned ad interim analysis was performed according to the Baeysian method for data monitoring of clinical trials accruing pts over several years. The aim of this analysis was to evaluate if the MANTA trial could be terminated because early results suggesting there is unlikely to be any treatment difference. A prior distribution was chosen to provide an estimate of initial beliefs concerning the size of the potential terapeutic effect. This analysis showed that there is only a small chance (11.7%) that there could be a 3 or more month difference between the 2 arms, adopting the stance of an enthusiast. Conclusions: After these data the trial was discontinued and the final analysis is ongoing. Final results from the MANTA trial will be presented at the meeting. No significant financial relationships to disclose.
FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis
Authors: Lalit Sehgal, Frank K Braun, Rohit Mathur, Sattva Neelapu, Larry W. Kwak, Zuzana Berkova, Felipe Samaniego
Journal: Blood (2013)
Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma
Authors: Laura Pasqualucci, Mara Compagno, Wei Keat Lim, Adina Grunn, Subhadra V Nandula, Marta Scandurra, Francesco Bertoni, Maurilio Ponzoni, Andrea Califano, Govind Bhagat, Amy Chadburn, Riccardo Dalla-Favera
Journal: Blood (2008)
Mitochondrial Mutation Rate, Spectrum and Heteroplasmy in <i>Caenorhabditis elegans</i> Spontaneous Mutation Accumulation Lines of Differing Population Size
Authors: Anke Konrad, Owen Thompson, Robert H. Waterston, Donald G. Moerman, Peter D. Keightley, Ulfar Bergthorsson, Vaishali Katju
Journal: Molecular Biology and Evolution (2017)

Mitochondrial genomes of metazoans, given their elevated rates of evolution, have served as pivotal markers for phylogeographic studies and recent phylogenetic events. In order to determine the dynamics of spontaneous mitochondrial mutations in small populations in the absence and presence of selection, we evolved mutation accumulation (MA) lines of Caenorhabditis elegans in parallel over 409 consecutive generations at three varying population sizes of N = 1, 10, and 100 hermaphrodites. The N =1 populations should have a minimal influence of natural selection to provide the spontaneous mutation rate and the expected rate of neutral evolution, whereas larger population sizes should experience increasing intensity of selection. New mutations were identified by Illumina paired-end sequencing of 86 mtDNA genomes across 35 experimental lines and compared with published genomes of natural isolates. The spontaneous mitochondrial mutation rate was estimated at 1.05 × 10-7/site/generation. A strong G/C→A/T mutational bias was observed in both the MA lines and the natural isolates. This suggests that the low G + C content at synonymous sites is the product of mutation bias rather than selection as previously proposed. The mitochondrial effective population size per worm generation was estimated to be 62. Although it was previously concluded that heteroplasmy was rare in C. elegans, the vast majority of mutations in this study were heteroplasmic despite an experimental regime exceeding 400 generations. The frequencies of frameshift and nonsynonymous mutations were negatively correlated with population size, which suggests their deleterious effects on fitness and a potent role for selection in their eradication.
PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.
Authors: Lucia De Franceschi, Giorgio Malpeli, Anne Janin, Aldo Scarpa, Christhophe Leboeuf, Orah Platt, Philippe Leboulch, Emmanuel Payen, Yves Beuzard, Carlo Brugnara
Journal: Blood (2004)
Leading Causes of Death in Nonmetropolitan and Metropolitan Areas— United States, 1999–2014
Authors: Ernest Moy, Macarena C. Garcia, Brigham Bastian, Lauren M. Rossen, Deborah D. Ingram, Mark Faul, Greta M. Massetti, Cheryll C. Thomas, Yuling Hong, Paula W. Yoon, Michael F. Iademarco
Journal: MMWR Surveillance Summaries (2017)

Higher rates of death in nonmetropolitan areas (often referred to as rural areas) compared with metropolitan areas have been described but not systematically assessed.1999-2014 DESCRIPTION OF SYSTEM: Mortality data for U.S. residents from the National Vital Statistics System were used to calculate age-adjusted death rates and potentially excess deaths for nonmetropolitan and metropolitan areas for the five leading causes of death. Age-adjusted death rates included all ages and were adjusted to the 2000 U.S. standard population by the direct method. Potentially excess deaths are defined as deaths among persons aged <80 years that exceed the numbers that would be expected if the death rates of states with the lowest rates (i.e., benchmark states) occurred across all states. (Benchmark states were the three states with the lowest rates for each cause during 2008-2010.) Potentially excess deaths were calculated separately for nonmetropolitan and metropolitan areas. Data are presented for the United States and the 10 U.S. Department of Health and Human Services public health regions.Across the United States, nonmetropolitan areas experienced higher age-adjusted death rates than metropolitan areas. The percentages of potentially excess deaths among persons aged <80 years from the five leading causes were higher in nonmetropolitan areas than in metropolitan areas. For example, approximately half of deaths from unintentional injury and chronic lower respiratory disease in nonmetropolitan areas were potentially excess deaths, compared with 39.2% and 30.9%, respectively, in metropolitan areas. Potentially excess deaths also differed among and within public health regions; within regions, nonmetropolitan areas tended to have higher percentages of potentially excess deaths than metropolitan areas.Compared with metropolitan areas, nonmetropolitan areas have higher age-adjusted death rates and greater percentages of potentially excess deaths from the five leading causes of death, nationally and across public health regions.Routine tracking of potentially excess deaths in nonmetropolitan areas might help public health departments identify emerging health problems, monitor known problems, and focus interventions to reduce preventable deaths in these areas.
G-CSF Mobilized Granulocyte Transfusions in 32 Pediatric Patients with Severe Infections after Chemotherapy Induced Neutropenia.
Authors: Lorenz Grigull, Nicole Pulver, Lilia Goudeva, Karl W. Sykora, Andreas Beilken, Hansjoerg Schmid, Karl Welte, Hansgert Heuft
Journal: Blood (2004)
Dual-targeted and pH-sensitive Doxorubicin Prodrug-Microbubble Complex with Ultrasound for Tumor Treatment
Authors: Wanxian Luo, Ge Wen, Li Yang, Jiao Tang, Jianguo Wang, Jihui Wang, Shiyu Zhang, Li Zhang, Fei Ma, Liling Xiao, Ying Wang, Yingjia Li
Journal: Theranostics (2017)

In this study, we investigated the potential of a dual-targeted pH-sensitive doxorubicin prodrug-microbubble complex (DPMC) in ultrasound (US)-assisted antitumor therapy. The doxorubicin prodrug (DP) consists of a succinylated-heparin carrier conjugated with doxorubicin (DOX) via hydrazone linkage and decorated with dual targeting ligands, folate and cRGD peptide. Combination of microbubble (MB) and DP, generated via avidin-biotin binding, promoted intracellular accumulation and improved therapeutic efficiency assisted by US cavitation and sonoporation. Aggregates of prepared DP were observed with an inhomogeneous size distribution (average diameters: 149.6±29.8 nm and 1036.2±38.8 nm, PDI: 1.0) while DPMC exhibited a uniform distribution (average diameter: 5.804±2.1 μm), facilitating its usage for drug delivery. Notably, upon US exposure, DPMC was disrupted and aggregated DP dispersed into homogeneous small-sized nanoparticles (average diameter: 128.6±42.3 nm, PDI: 0.21). DPMC could target to angiogenic endothelial cells in tumor region via αvβ3-mediated recognition and subsequently facilitate its specific binding to tumor cells mediated via recognition of folate receptor (FR) after US exposure. In vitro experiments showed higher tumor specificity and killing ability of DPMC with US than free DOX and DP for breast cancer MCF-7 cells. Furthermore, significant accumulation and specificity for tumor tissues of DPMC with US were detected using in vivo fluorescence and ultrasound molecular imaging, indicating its potential to integrate tumor imaging and therapy. In particular, through inducing apoptosis, inhibiting cell proliferation and antagonizing angiogenesis, DPMC with US produced higher tumor inhibition rates than DOX or DPMC without US in MCF-7 xenograft tumor-bearing mice while inducing no obvious body weight loss. Our strategy provides an effective platform for the delivery of large-sized or aggregated particles to tumor sites, thereby extending their therapeutic applications in vivo.
Folic Acid Supplementation for the Prevention of Neural Tube Defects
Authors: Kirsten Bibbins-Domingo, David C. Grossman, Susan J. Curry, Karina W. Davidson, John W. Epling, Francisco A.R. García, Alex R. Kemper, Alex H. Krist, Ann E. Kurth, C. Seth Landefeld, Carol M. Mangione, William R. Phillips, Maureen G. Phipps, Michael P. Pignone, Michael Silverstein, Chien-Wen Tseng
Journal: JAMA (2017)

<h3>Importance</h3> Neural tube defects are among the most common major congenital anomalies in the United States and may lead to a range of disabilities or death. Daily folic acid supplementation in the periconceptional period can prevent neural tube defects. However, most women do not receive the recommended daily intake of folate from diet alone. <h3>Objective</h3> To update the 2009 US Preventive Services Task Force (USPSTF) recommendation on folic acid supplementation in women of childbearing age. <h3>Evidence Review</h3> In 2009, the USPSTF reviewed the effectiveness of folic acid supplementation in women of childbearing age for the prevention of neural tube defects in infants. The current review assessed new evidence on the benefits and harms of folic acid supplementation. <h3>Findings</h3> The USPSTF assessed the balance of the benefits and harms of folic acid supplementation in women of childbearing age and determined that the net benefit is substantial. Evidence is adequate that the harms to the mother or infant from folic acid supplementation taken at the usual doses are no greater than small. Therefore, the USPSTF reaffirms its 2009 recommendation. <h3>Conclusions and Recommendation</h3> The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400-800 µg) of folic acid. (A recommendation)
Interim Analysis of Randomized Phase II Study of Recombinant Human Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy with Stem Cell Transplantation for Hematologic Malignancies
Authors: Ji-Won Kim, Kyung Im Kim, Hyun Jung Lee, Byung-Su Kim, Soo-Mee Bang, Inho Kim, Jung Mi Oh, Sung-Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim
Journal: Blood (2010)
47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma
Authors: Xenofon Papanikolaou, Caleb K. Stein, Ricky D Edmondson, Veronica Macleod, Ruslana Tytarenko, Bart Barlogie, Joshua Epstein, Christoph Heuck
Journal: Blood (2015)
The Risk of Progression in 127 Early Stage CLL Patients. Prognostic Significance of Mutational Status, ZAP-70 and CD-38.
Authors: Alessandra Perego, Fausto Rossini, Daniele Perego, Andrea Soccodato, Pierluigi Tramacere, Chiara Colombo, Fabio Rossi, Tiziana Speranza, Paolo Mocarelli, Enrico Maria Pogliani
Journal: Blood (2006)
Age under 40 Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant Despite High Response Rates.
Authors: Parneet K. Cheema, Sahar Zadeh, Donna Reece, Christine I. Chen, Suzanne Trudel, Vishal Kukreti, Joseph R. Mikhael
Journal: Blood (2007)
The Landscape of Myeloid Neoplasms with Isochromosome 17q Discloses a Specific Mutation Profile and Is Characterized By an Accumulation of Prognostically Adverse Molecular Markers
Authors: Manja Meggendorfer, Claudia Haferlach, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2015)
Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children’s Oncology Group (COG) Study.
Authors: Yoav H. Messinger, Rodney Higgins, Meenakshi Devidas, Stephen P. Hunger, Andrew J. Carroll, Nyla A. Heerema
Journal: Blood (2008)
Hemoglobin Köln in a Black: Preand PostSplenectomy Red Cell Survival (DF32P and 51Cr) and the Pathogenesis of Hemoglobin Instability
Authors: Paul R. Pedersen, Paul R. McCurdy, R. N. Wrightstone, J. B. Wilson, L. L. Smith, T. H. J. Huisman
Journal: Blood (1973)
TCT-147 High dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention: Prespecified Substudy of a Prospective Randomized Clinical trial
Authors: Sang-Ho Jo, Hyun-Sook Kim, Jin-Ho Choi, Seung-Hyuk Choi, Joo-Yong Hahn, Sung Yun Lee, Young Bin Song
Journal: Journal of the American College of Cardiology (2012)
High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study
Authors: Shin Young Hyun, Yu Ri Kim, yun Deok Kim, Do Yoo Whang, Soo Jeong Kim, June-Won Cheong, Hong Ghi Lee, Deok-Hwan Yang, Jae Sook Ahn, Won-Sik Lee, Ryu Hon Mo, Young-Rok Do, Ho Sup Lee, Jae Hoon Lee, Sung Yong Oh, Cheolwon Suh, Ho-Young Yhim, Jin Seok Kim
Journal: Blood (2012)
Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients
Authors: Gabriele Buda, Enrico Orciuolo, Sara Galimberti, Matteo Pelosini, Mario Petrini
Journal: Blood (2010)
The Mystery of the Interstitial Cells in the Urinary Bladder
Authors: Sang Don Koh, Haeyeong Lee, Sean M. Ward, Kenton M. Sanders
Journal: The Annual Review of Pharmacology and Toxicology (2017)

Intrinsic mechanisms to restrain smooth muscle excitability are present in the bladder, and premature contractions during filling indicate a pathological phenotype. Some investigators have proposed that c-Kit + interstitial cells (ICs) are pacemakers and intermediaries in efferent and afferent neural activity, but recent findings suggest these cells have been misidentified and their functions have been misinterpreted. Cells reported to be c-Kit + cells colabel with vimentin antibodies, but vimentin is not a specific marker for c-Kit + cells. A recent report shows that c-Kit + cells in several species coexpress mast cell tryptase, suggesting that they are likely to be mast cells. In fact, most bladder ICs labeled with vimentin antibodies coexpress platelet-derived growth factor receptor α (PDGFRα). Rather than an excitatory phenotype, PDGFRα + cells convey inhibitory regulation in the detrusor, and inhibitory mechanisms are activated by purines and stretch. PDGFRα + cells restrain premature development of contractions during bladder filling, and overactive behavior develops when the inhibitory pathways in these cells are blocked. PDGFRα + cells are also a prominent cell type in the submucosa and lamina propria, but little is known about their function in these locations. Effective pharmacological manipulation of bladder ICs depends on proper identification and further study of the pathways in these cells that affect bladder functions.
Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML
Authors: Steffan T. Nawrocki, Yingchun Han, Ronan LE Moigne, Valeria Visconte, Bartlomiej Przychodzen, Mark Rolfe, Stevan Djakovic, Daniel Anderson, David Wustrow, Han-Jie Zhou, Steve Wong, Anjali Advani, Hetty E. Carraway, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Kevin R. Kelly, Jennifer S. Carew
Journal: Blood (2015)